| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
We investigated inhalation effects on diaphragm muscle contractility using a combination of inhaled corticosteroid (ICS) and long-acting β2- agonist (LABA), and a long-acting muscarinic antagonist (LAMA). The ICS/LABA inhalation significantly increased force-frequency (F/f) curves at 1 h after inhalation. Endotoxin injection resulted in a downward shift in F/f curves at 4 h and induced NO production, however ICS/LABA inhalation prevented endotoxin effects. These results indicate that the inhalation of ICS/LABA potentiates diaphragm muscle contractility, and it seems a benefit for the patients with bronchial asthma.We also investigated inhalation effects of long-acting muscarinic antagonist (LAMA). LAMA inhalation induced an increase of muscle contractility at 4 h after its inhalation and inhibited the effects of endotoxin by reducing NO production. These results indicate that LAMA is beneficial for the patients with COPD because it helps prevent diaphragm muscle weakness.
|
